Buy Rating on Olema Pharmaceuticals Amidst Promising Oncology Developments and Competitive Edge
TipRanksApr 12 11:55 ET
FATE, ALPN and RLAY Are Among After Hour Movers
Seeking AlphaApr 10 17:20 ET
Olema Oncology to Participate in Canaccord Genuity 2024 Horizons in Oncology Virtual Conference
SAN FRANCISCO, April 08, 2024 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (("Olema", "Olema Oncology", NASDAQ:OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development, and
GlobeNewswireApr 8 16:30 ET
Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
SAN FRANCISCO, April 02, 2024 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. ("Olema" or "Olema Oncology", Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, develo
GlobeNewswireApr 2 16:29 ET
Express News | Goldman Sachs Initiates Coverage On Olema Pharmaceuticals With Buy Rating, Announces Price Target of $24
Moomoo 24/7Apr 2 07:09 ET
Olema Pharmaceuticals(OLMA.US) Director Sells US$219.4K in Common Stock
$Olema Pharmaceuticals(OLMA.US)$ Director Harmon Cyrus sold 20,000 shares of Common Stock on Mar 28, 2024 at an average price of $10.97 for a total value of $219.4K.Source: Announcement What is statem
moomoo NewsMar 29 17:41 ET
Form 144 | Olema Pharmaceuticals(OLMA.US) Director Proposes to Sell 219.33K in Common Stocks
SEC FILLINGS DISCLOSED/ Mar 28, $Olema Pharmaceuticals(OLMA.US)$ Director Harmon Cyrus intends to sell 20,000 shares of its common stock on Mar 28, with a total market value of approximately $219.33K.
moomoo NewsMar 28 11:10 ET
Buy Rating for Olema Pharmaceuticals Based on Promising Palazestrant and Ribociclib Combination in ER+ Breast Cancer Treatment
TipRanksMar 12 09:45 ET
Oppenheimer Reiterates Outperform on Olema Pharmaceuticals, Maintains $21 Price Target
Oppenheimer analyst Matthew Biegler reiterates Olema Pharmaceuticals with a Outperform and maintains $21 price target.
Analyst UpgradesMar 12 08:18 ET
Oppenheimer Sticks to Its Buy Rating for Olema Pharmaceuticals (OLMA)
TipRanksMar 12 08:05 ET
Buy Rating Justified for Olema Pharmaceuticals Amidst Promising Trial Results and Significant Market Opportunity
TipRanksMar 12 08:05 ET
Olema Pharmaceuticals Is Maintained at Buy by HC Wainwright & Co.
Olema Pharmaceuticals Is Maintained at Buy by HC Wainwright & Co.
Dow JonesMar 12 06:49 ET
Express News | HC Wainwright & Co. Maintains Buy on Olema Pharmaceuticals, Lowers Price Target to $25
Moomoo 24/7Mar 12 06:39 ET
Olema Pharmaceuticals Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 03/12/2024 88.68% HC Wainwright & Co. $28 → $25 Maintains Buy 01/30/2024 50.94% Citigroup → $20 Initiates
BenzingaMar 12 06:33 ET
Optimistic Outlook on Olema Pharmaceuticals: A Comprehensive Analysis of Palazestrant's Clinical Advancements and Future Potential
TipRanksMar 12 06:26 ET
Strong Clinical Progress and Market Potential: Buy Rating for Olema Pharmaceuticals' Palazestrant
TipRanksMar 11 20:25 ET
Express News | Olema Pharmaceuticals Q4 EPS $(0.49) Misses $(0.48) Estimate
Moomoo 24/7Mar 11 16:04 ET
Press Release: Olema Oncology Reports Fourth Quarter and Full-Year 2023 Financial Results and Provides Corporate Update
Olema Oncology Reports Fourth Quarter and Full-Year 2023 Financial Results and Provides Corporate Update -- Presented compelling clinical results for palazestrant both as a monotherapy and i
Dow JonesMar 11 16:03 ET
Olema Pharmaceuticals 4Q Loss/Shr 49c >OLMA
Olema Pharmaceuticals 4Q Loss/Shr 49c >OLMA
Dow JonesMar 11 16:03 ET
Big Pharma Patent Cliffs Seen Fueling Oncology M&A This Year
Seeking AlphaMar 10 13:08 ET
No Data
No Data